FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
April 24, 2007
Report of Foreign issuer
Pursuant
to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
(Commission file number) 0 - 017444
Akzo
Nobel N.V.
(Translation of registrants name into English)
76,
Velperweg, 6824 BM Arnhem, the Netherlands
(Address of principal executive offices)
SIGNATURES
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of
1934 the registrant has duly caused this report to be signed on its behalf
of
the undersigned, thereto duly authorized.
Akzo Nobel N.V.
Name : | R.J. Frohn | Name : | J.J.M. Derckx |
Title : | Chief Financial Officer | Title : | Director Financial Reporting |
Dated : April 24, 2007
2 |
Report
for the 1st quarter of 2007
|
Highlights
|
Strong quarter for the new Akzo Nobel | |
| 6% autonomous growth for Coatings and Chemicals |
| Operational results increase 18%; EBITDA margin further improved to 12.3% |
| Coatings higher EBITDA margin on 8% revenues growth |
| Chemicals strong EBITDA margin maintained on 4% autonomous growth |
| Good quarter for Organon and Intervet |
| EUR 11 billion cash deal for Organon BioSciences announced |
| EUR 1.6 billion share buyback program commencing on May 3, 2007 |
Millions
of euros (EUR) or %
|
1st
quarter
|
||||||
|
|
|
|
|
|
|
|
2007 | 2006 | Δ% | |||||
Continuing operations (Coatings and | |||||||
Chemicals) before incidentals: | |||||||
Revenues | 2,501 | 2,472 | 1 | ||||
EBITDA | 307 | 279 | 10 | ||||
EBITDA margin | 12.3 | 11.3 | |||||
EBIT | 219 | 185 | 18 | ||||
Net income from continuing | |||||||
operations | 133 | 113 | 18 | ||||
Net income from discontinued | |||||||
operations (Organon BioSciences) | 111 | 102 | 9 | ||||
|
|
|
|
|
|
|
|
Net income (attributable | |||||||
to equity holders) | 246 | 249 | (1 | ) | |||
Earnings per share, in EUR | 0.86 | 0.87 | |||||
Invested capital | 8,296 | 8,060 | 1 | ||||
Moving average ROI | 13.7 | 13.3 | |||||
Net interest-bearing borrowings | 955 | 1,090 | 1 | ||||
|
|
|
|
|
|
|
|
1 At December 31. |
Akzo
Nobel
|
3
|
Organon
BioSciences treated as discontinued operation
On March 12, 2007, the company
announced its intention to divest Organon BioSciences (OBS) to Schering-Plough,
following their EUR 11 billion binding cash offer. As a consequence, in accordance
with IFRS 5, the OBS activities qualify as so-called discontinued operation.
As a result, going forward no depreciation or amortization is recognized anymore
for the OBS activities, which increased pre-tax results by EUR 5 million.
The continuing operations consist of the Coatings and Chemicals activities.
Revenues
6% autonomous growth
Revenues of EUR
2.5 billion were up 1% on last year. Autonomous growth was 6%. Volumes increased
3%, with Coatings as the main contributor. Average selling prices were 3%
higher at both Coatings and Chemicals. Currency translation had a 3% negative
effect in the quarter, mainly attributable to the weaker U.S. dollar and the
Asian currencies. Acquisitions and divestments on balance had a 2% negative
impact. Sico formed the main acquisition at Coatings. Divestments mainly related
to the Chemicals divestment program. Total revenues of Akzo Nobel developed
as follows:
predominantly the sale of a Coatings plant near Barcelona, Spain. For further details see the table on page 12.
Net financing charges decreased from EUR 34 million to EUR 27 million, mainly due to higher cash and cash equivalents and lower short-term borrowings. Interest coverage in the first quarter was 7.9 (2006: 6.8).
The share in profit of associates decreased from EUR 20 million to EUR 12 million in 2007. The 2006 number included incidental gains of EUR 6 million related to Acordis. Operational results of Flexsys were somewhat lower in the quarter.
The income tax charge in the first quarter of 2007 was 28%, compared with 29% in 2006, due to lower tax rates in certain countries, including the Netherlands.
Net income
virtually unchanged
The combination of improved
operational earnings and lower incidentals resulted in 1% lower net income of
EUR 246 million, which include both continuing and discontinued operations.
Earnings per share were EUR 0.86 (2006: EUR 0.87).
In
%
|
Total
|
Volume
|
Price
|
Currency
translation
|
Acquisitions/divestments
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
Coatings
|
8
|
|
5
|
|
3
|
|
(4
|
)
|
4
|
||
Chemicals
|
1
|
1
|
3
|
(2
|
)
|
(1
|
)
|
||||
Akzo
Nobel
|
1
|
3
|
3
|
(3 |
)
|
(2
|
)1
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
1
Included is the effect of the divestment of certain activities in
Other.
|
EBITDA
improved 10%
EBITDA before incidentals
in the first quarter amounted to EUR 307 million, up 10% on the EUR 279 million
of 2006. Coatings was the main contributor to this increase. This translated
into an EBITDA margin of 12.3% (2006: 11.3%). At Chemicals, the EBITDA margin
was maintained at 17.9%.
Operational
earnings boost of 18%
Before incidentals, operating
income rose 18% from EUR 185 million to EUR 219 million. The EBIT margin
was 8.8%, against 7.5% in the first quarter of 2006. Both Coatings and Chemicals
realized strong autonomous growth and cost savings. Almost all activities
did better than last year. Substantial further growth was achieved in the
emerging markets, while most businesses in Europe also improved their performance.
The improvement in EBIT reported as Other was caused by favorable IAS 39 fair value adjustments and better results of the captive insurance companies due to lower damages. Including incidentals, operating income decreased 9% to EUR 212 million, with an EBIT margin of 8.5% (2006: 9.4%). Incidentals in 2007 were a net loss of EUR 7 million, compared with a gain of EUR 47 million in the first quarter of 2006. The 2006 figure was positive due to sizable gains on divestments in that quarter,
Before incidentals, net
income rose 13% from EUR 215 million to
EUR 244 million. Net income breaks down as follows:
Net
income before
|
|||||||||
Millions
of euros
|
incidentals
|
Net
income
|
|||||||
|
|
|
|
|
|
|
|
|
|
2007 | 2006 | 2007 | 2006 | ||||||
Continuing operations | 133 | 113 | 134 | 150 | |||||
Discontinued operations | 111 | 102 | 112 | 99 | |||||
|
|
|
|
|
|
|
|
|
|
Akzo Nobel | 244 | 215 | 246 | 249 | |||||
|
|
|
|
|
|
|
|
|
Workforce
Akzo Nobels
workforce at Coatings and Chemicals consisted of 42,880 employees, up compared
with the 42,690 employees at year-end 2006. The number of employees at Organon
BioSciences was 19,140.
Trading
conditions in 2007
Akzo Nobel is well positioned
for profitable growth. Assuming that no significant changes in the major economies
of the world occur, Akzo Nobel believes that it is well placed to outgrow its
markets and further improve the financial returns in Coatings and Chemicals.
Highlights 1st quarter | |
Report for the 1st quarter of 2007 |
4 | Report for the 1st quarter of 2007 |
Akzo Nobel Coatings higher EBITDA margin on 8% revenues growth |
| Revenues up 8% autonomous growth and acquisitions |
| Currency headwinds 4% on revenues |
| Emerging markets drive growth; European businesses improving |
| EBITDA up 11% |
| Decorative Coatings promising start to the year; volume growth and margin improvement |
| Continued raw material pressure particularly at industrial businesses |
Millions
of euros or %
|
1st
quarter
|
||||||||
|
|
|
|
|
|
|
|
||
2007 | 2006 | 1 | Δ% | ||||||
Revenues | |||||||||
Decorative Coatings | 549 | 474 | |||||||
Industrial activities | 495 | 474 | |||||||
Marine & Protective Coatings | 304 | 270 | |||||||
Car Refinishes | 230 | 234 | |||||||
Intragroup revenues/other | (24 | ) | (18 | ) | |||||
|
|
||||||||
Total | 1,554 | 1,434 | 8 | ||||||
|
|
|
|
|
|
|
|
||
EBITDA before incidentals | 153 | 138 | 11 | ||||||
EBITDA margin | 9.8 | 9.6 | |||||||
EBIT before incidentals | 117 | 104 | 13 | ||||||
EBIT margin | 7.5 | 7.3 | |||||||
|
|
|
|
|
|
|
|
||
EBIT (operating income) | 114 | 209 | (45 | ) | |||||
EBIT margin | 7.3 | 14.6 | |||||||
Capital expenditures | 31 | 22 | |||||||
Invested capital | 2,754 | 2,653 | 2 | ||||||
Moving average ROI | 19.9 | 19.9 | |||||||
Number of employees | 31,990 | 31,660 | 2 | ||||||
|
|
|
|
|
|
|
|
1 | 2006 figures have been restated for minor changes in the business unit structure. |
2 | At December 31. |
Results
Coatings achieved a strong
quarter with revenues growth of 8% on last year. Autonomous growth was 8%,
thanks to 5% higher volumes and 3% price increases. Acquisitions added 4%,
while the currency impact was 4% negative.
EBITDA before incidentals grew 11% to EUR 153 million, with the EBITDA margin improving from 9.6% to 9.8%.
Before incidentals, operating income grew 13% to EUR 117 million, with an increased EBIT margin of 7.5%. Various restructuring measures implemented in recent years improved our cost competitiveness in mature markets, while price increases across the board are starting to restore margins that were affected by the raw materials price hike that began in 2005.
Decorative
Coatings
Decorative Coatings had
a promising start to the year. Double-digit revenues growth was driven by
acquisitions and higher volumes. Sales in Europe were strong due to the overall
improved economic climate and the mild winter conditions. Sales volumes at
Building Adhesives were up 8%, with growth in all regions. There is increased
management focus on the turnaround of underperforming activities. Earnings
of Sico (acquired in May 2006) are developing favorably.
Akzo Nobel |
5
|
Industrial
activities
The industrial activities
continued to deliver a healthy performance, although the slowdown in the U.S.
housing industry affected parts of the business, including our supply to Asias
export industries. Western European-based businesses all had a good start to
2007, while in Asia and Eastern Europe high growth rates continued, driven by
strong demand in commercial construction. The Plastic Coatings activity is growing
rapidly due to the further penetration in the electronics markets. Powder Coatings
improved top-line and bottom-line results compared to the first quarter of last
year on strong demand and cost reduction programs. Business was particularly
good in Western Europe, where double-digit growth was realized in the mature
markets due to increased industry demand. Sales were also strong in Asia Pacific.
New plants in Russia and China were started up to serve local customers.
Marine
& Protective Coatings
Marine & Protective Coatings
again achieved double-digit revenues growth, as a result of the strong expansion
in the Asia Pacific region (in particular China, India, and Singapore). Marines
profits are still suffering from raw material price pressure. Demand for protective
coatings was strong, both in the onshore and offshore markets in Asia Pacific.
The promising Intersleek® 900 product for protective applications
was launched in February. First orders have been placed, and deliveries will
start in the course of 2007. At Aerospace Coatings, there was solid demand from
the large manufacturers and a move into new territories by other manufacturers.
Car Refinishes
Car Refinishes improved EBIT
margins as a result of the cost saving measures of recent years and positive
volume developments. The flat top-line is the result of unfavorable U.S. dollar-related
currencies. Strong focus on sales to major customers in Europe resulted in volume
gains, while the changeover to waterborne basecoats continued. The North American
commercial vehicle business was strong, while volume growth in China and India
was above market rates. Our Sign Coatings activity is expanding into Asia.
Case study
Akzo Nobels
Sikkens coatings brand has introduced Rubbol® XD, an innovative
high gloss finish, which offers unprecedented outdoor durability.
Based on a unique and patented binder technology, Rubbol XD is several years ahead of European legislation which will limit the use of solvents from 2010 onward. Rubbol XD stands for eXtremely Durable. Although application and flow characteristics are comparable to Sikkens current top productRubbol SBits aesthetic and durability characteristics are considerably better.
The technical recoatability time of eight to ten years offers major benefits for both the painter and the customer. Buildings need to be recoated less frequently and look exceptional in the meantime.
Akzo Nobel Coatings | |
Report for the 1st quarter of 2007 |
6 | Report for the 1st quarter of 2007 |
Akzo Nobel Chemicals strong EBITDA margin maintained on 4% autonomous growth |
| Autonomous growth of 4%; negative currency impact of 2% |
| Operational result up 6%; margin management programs paying off |
| EBITDA margin of 17.9% |
| Raw materials and energy pressure successfully countered |
| Strong performance across all business areas |
Millions
of euros or %
|
1st
quarter
|
|||||||
|
|
|
|
|
|
|
|
|
2007
|
2006
|
1
|
Δ%
|
|||||
Revenues
|
||||||||
Pulp
& Paper Chemicals
|
245
|
247
|
||||||
Base
Chemicals
|
225
|
240
|
||||||
Functional
Chemicals
|
200
|
191
|
||||||
Surfactants
|
139
|
138
|
||||||
Polymer
Chemicals
|
132
|
132
|
||||||
Intragroup
revenues/other
|
(24
|
)
|
(36
|
)
|
||||
|
|
|||||||
Total
|
917
|
912
|
1
|
|||||
|
|
|
|
|
|
|
|
|
EBITDA
before incidentals
|
164
|
163
|
1
|
|||||
EBITDA
margin
|
17.9
|
17.9
|
||||||
EBIT
before incidentals
|
115
|
108
|
6
|
|||||
EBIT
margin
|
12.5
|
11.8
|
||||||
|
|
|
|
|
|
|
|
|
EBIT
(operating income)
|
111
|
80
|
39
|
|||||
EBIT
margin
|
12.1
|
8.8
|
||||||
Capital
expenditures
|
50
|
40
|
||||||
Invested
capital
|
1,959
|
1,960
|
2
|
|||||
Moving
average ROI
|
18.3
|
17.9
|
||||||
Number
of employees
|
9,180
|
9,300
|
2
|
|||||
|
|
|
|
|
|
|
|
1
|
2006 figures have been restated for minor changes in the business unit structure. In addition, the activities (to be) divested have now been included under Other at company level. |
2
|
At
December 31.
|
Results
Revenues increased by 1%
to EUR 917 million. Volume growth of 1% and 3% price increases were partially
offset by a negative currency impact of 2% (primarily the U.S. dollar) and a
1% divestment effect.
EBITDA was virtually unchanged at EUR 164 million and the EBITDA margin was maintained at 17.9%.
Operating income before incidentals amounted to EUR 115 mln, 6% better than in the previous year. The EBIT margin improved to 12.5%, as a result of the focused margin management programs at all units. The moving average ROI improved from 17.9% to 18.3%.
Pulp &
Paper Chemicals
In Pulp & Paper
Chemicals, autonomous growth of 1% from higher selling prices was offset by
negative currency translation effects and the transfer of the U.S. hydrogen
peroxides businesses to the OCI joint venture. Bleaching Chemicals margins are
improving as selling price increases are being implemented, in particular in
Europe and the Americas. Paper Chemicals achieved good volume growth in Asia.
The favorable product mix and cost saving programs were the main contributors
to the substantially improved operational performance in the first quarter of
2007.
Akzo Nobel |
7
|
Base Chemicals
Base Chemicals turned
in a strong EBIT(DA) increase, mainly driven by Chlor Alkali (strong demand
for chlorine and caustic) and Energy. Revenues were negatively affected (6%)
by the outsourcing of technical services in Rotterdam and Delfzijl, the Netherlands.
High production levels were achieved at both sites, with a record volume for
Rotterdam in March. In Delfzijl, the new MCA plant is now fully operational.
Road Salts earnings were lower than in the previous year, due to the very
mild winter in Europe.
Functional
Chemicals
Functional Chemicals had
a good first quarter of 2007, with revenues growth of 5%. Margins were sustained
with a good performance, particularly of Ethylene Amines and Salt Specialties,
despite ongoing raw material price pressure. The 2006 production problems at
Ethylene Amines were resolved. Chelates, Sulfur Products, and Cellulosic Specialties
achieved increased margins on higher volumes and prices.
Surfactants
Revenues of Surfactants
were 1% higher than the previous year, despite a negative currency impact of
4%. A clear volume increase in China, the launch of our Feixiang Chemicals joint
venture, and higher sales in agro and industrial applications (asphalt and mining)
all contributed to growth. Our plants are running at high capacity utilization
levels. Operating income was ahead of the first quarter of 2006 in spite of
high raw material prices.
Polymer
Chemicals
Polymer Chemicals revenues
were unchanged compared to the same period in the previous year. Autonomous
growth of 4% was fully offset by the negative currency impact. Sales volumes
improved on last year despite lower demand in the U.S. PVC market, driven by
a weakening of the U.S. housing industry. Operating income was ahead of 2006
due to cost savings and margin management.
Divestment
program
The divestment program started
in 2005 has been completed after the recent announcements of the sale of the
Akcros Chemicals PVC Additives business and of the European-based Methyl Amines
and Chlorine Chloride (MACC) activities. The sale of Akzo Nobels 50%-stake
in the Flexsys joint venture is expected to be concluded in the second quarter
of 2007.
Case study
Akzo Nobel
has invested nearly EUR 7 million to install a woodchip-fired boiler at its
salt facility in Mariager, Denmark. The boiler will be able to supply around
half of the facilitys demand for steam, which is needed to produce the
salt.
The boiler creates flexibility for the company in relation to the choice of fuel, making us less dependent on natural gas, which is sold for very high prices at the moment.
Woodchips are a cheaper and more sustainable fuel. Woodchips are CO2-neutral as the emitted CO2 is balanced with the growth of forests. Moreover the woodchips are produced through the process of forest maintenance; they are not won at the expense of the environment.
Akzo Nobel Chemicals | |
Report for the 1st quarter of 2007 |
8 | Report for the 1st quarter of 2007 |
Consolidated statement of income |
Millions
of euros
|
1st
quarter
|
||||||
|
|
|
|
|
|
|
|
2007 | 2006 | Δ% | |||||
Continuing operations | |||||||
Revenues | 2,501 | 2,472 | 1 | ||||
Cost of sales | (1,532 | ) | (1,560 | ) | |||
|
|
||||||
Gross profit | 969 | 912 | |||||
Selling expenses | (549 | ) | (562 | ) | |||
Research and development expenses | (71 | ) | (73 | ) | |||
General and administrative expenses | (162 | ) | (160 | ) | |||
Other operating income | 25 | 115 | |||||
|
|
||||||
Operating income (EBIT) | 212 | 232 | (9 | ) | |||
Financing income | 33 | 28 | |||||
Financing expenses | (60 | ) | (62 | ) | |||
|
|
||||||
Operating income less financing income and expenses | 185 | 198 | |||||
Share in profit of associates | 12 | 20 | |||||
|
|
||||||
Profit before tax | 197 | 218 | |||||
Income taxes | (55 | ) | (64 | ) | |||
|
|
||||||
Profit for the period from continuing operations | 142 | 154 | (8 | ) | |||
Discontinued operations (Organon BioSciences) | |||||||
Profit for the period from discontinued operations | 112 | 99 | |||||
|
|
||||||
Profit for the period | 254 | 253 | | ||||
|
|
|
|
|
|
|
|
Attributable to: | |||||||
Equity holders of the company (net income) | 246 | 249 | (1 | ) | |||
Minority interest | 8 | 4 | |||||
|
|
||||||
Profit for the period | 254 | 253 | | ||||
Income per share, in EUR: | |||||||
basic | 0.86 | 0.87 | |||||
diluted | 0.85 | 0.87 | |||||
|
|
|
|
|
|
|
|
Interest coverage | 7.9 | 6.8 | |||||
|
|
|
|
|
|
|
Akzo
Nobel
|
9
|
|
Condensed consolidated balance sheet |
Millions
of euros
|
March 31, 2007 |
Dec
31, 2006 pro forma
|
Dec
31, 2006
|
||||
|
|
|
|
|
|
|
|
Property, plant and equipment | 2,228 | 2,249 | 3,346 | ||||
Intangible assets | 529 | 536 | 682 | ||||
Financial noncurrent assets | 1,337 | 1,351 | 1,706 | ||||
|
|
|
|||||
Total noncurrent assets | 4,094 | 4,136 | 5,734 | ||||
Inventories | 1,220 | 1,190 | 2,042 | ||||
Receivables | 2,399 | 2,111 | 2,919 | ||||
Cash and cash equivalents | 1,904 | 1,871 | 1,871 | ||||
Assets held for sale | 3,486 | 3,477 | 219 | ||||
|
|
|
|||||
Total current assets | 9,009 | 8,649 | 7,051 | ||||
|
|
|
|||||
Total assets | 13,103 | 12,785 | 12,785 | ||||
|
|
|
|||||
Akzo Nobel N.V. shareholders equity | 4,396 | 4,144 | 4,144 | ||||
Minority interest | 117 | 119 | 119 | ||||
|
|
|
|||||
Total equity | 4,513 | 4,263 | 4,263 | ||||
Provisions | 1,856 | 1,910 | 2,132 | ||||
Deferred income | 7 | ||||||
Deferred tax liabilities | 153 | 149 | 174 | ||||
Long-term borrowings | 2,532 | 2,505 | 2,551 | ||||
|
|
|
|||||
Total noncurrent liabilities | 4,541 | 4,564 | 4,864 | ||||
Short-term borrowings | 327 | 304 | 410 | ||||
Current payables | 2,609 | 2,486 | 3,223 | ||||
Liabilities held for sale | 1,113 | 1,168 | 25 | ||||
|
|
|
|||||
Total current liabilities | 4,049 | 3,958 | 3,658 | ||||
|
|
|
|||||
Total equity and liabilities | 13,103 | 12,785 | 12,785 | ||||
|
|
|
|||||
Shareholders equity per share, in EUR | 15.28 | 14.44 | |||||
Number of shares outstanding, in millions | 287.7 | 287.0 | |||||
Gearing | 0.21 | 0.26 | |||||
Invested capital | 8,296 | 8,060 | |||||
|
|
|
|
|
|
|
In the December 31, 2006 pro forma column, Organon BioSciences has been treated as if it would qualify as discontinued operation as of that date.
Consolidated statement of income | |
Condensed consolidated balance sheet | |
Report for the 1st quarter of 2007 |
10 | Report for the 1st quarter of 2007 |
Condensed consolidated statement of cash flows |
Millions
of euros
|
1st
quarter
|
||||||||
|
|
|
|
|
|
|
|
|
|
2007 | 2006 | 1 | |||||||
Profit for the period | 254 | 253 | |||||||
Income discontinued operations | (112 | ) | (99 | ) | |||||
Adjustments to reconcile earnings to cash generated from operating activities: | |||||||||
Depreciation and amortization | 88 | 94 | |||||||
Impairment losses | | 5 | |||||||
Financing income and expenses | 27 | 34 | |||||||
Share in profit of associates | (12 | ) | (14 | ) | |||||
Income taxes | 55 | 64 | |||||||
|
|
||||||||
Operating profit before changes in working capital and provisions | 300 | 337 | |||||||
Changes in working capital | (204 | ) | (241 | ) | |||||
Changes in provisions | (71 | ) | 50 | ||||||
Other | (2 | ) | 5 | ||||||
|
|
||||||||
(277 | ) | (186 | ) | ||||||
|
|
||||||||
Cash generated from operating activities | 23 | 151 | |||||||
Interest paid | (12 | ) | (11 | ) | |||||
Income taxes paid | (68 | ) | (32 | ) | |||||
Pre-tax gain on divestments | 8 | (128 | ) | ||||||
|
|
||||||||
(72 | ) | (171 | ) | ||||||
|
|
||||||||
Net cash from operating activities | (49 | ) | (20 | ) | |||||
Capital expenditures | (83 | ) | (66 | ) | |||||
Interest received | 9 | 10 | |||||||
Repayments from associates | 18 | 7 | |||||||
Dividends from associates | 3 | 2 | |||||||
Acquisition of consolidated companies 2 | | (33 | ) | ||||||
Proceeds from sale of interests2 | 29 | 95 | |||||||
Other changes in noncurrent assets | 9 | 22 | |||||||
|
|
||||||||
Net cash from investing activities | (15 | ) | 37 | ||||||
Changes in borrowings | 22 | 28 | |||||||
Issue of shares | 35 | 5 | |||||||
Dividends | (8 | ) | (2 | ) | |||||
|
|
||||||||
Net cash from financing activities | 49 | 31 | |||||||
|
|
||||||||
Net cash provided by/(used for) continuing operations | (15 | ) | 48 | ||||||
Cash flows from discontinued operations | |||||||||
Net cash from operating activities | 92 | 92 | |||||||
Net cash from investing activities | (48 | ) | (24 | ) | |||||
Net cash from financing activities | 4 | (12 | ) | ||||||
|
|
||||||||
48 | 56 | ||||||||
|
|
||||||||
Net change in cash and cash equivalents of continued | |||||||||
and discontinued operations | 33 | 104 | |||||||
Cash and cash equivalents at January 1 | 1,871 | 1,486 | |||||||
Effect of exchange rate changes on cash and cash equivalents | | (6 | ) | ||||||
|
|
||||||||
Cash and cash equivalents at March 31 | 1,904 | 1,584 | |||||||
|
|
|
|
|
|
|
|
|
1 Reclassified
for comparative purposes.
2 Net of cash acquired or disposed of.
Akzo
Nobel
|
11
|
Changes in equity
Millions
of euros
|
Sub-
scribed
share
capital
|
Additional
paid-in
capital
|
Change
in
fair
value
of
derivatives
|
Cumulative
translation
reserves
|
Other
(statutory)
reserves
and
undistribu-
ted
profits
|
Share-
holders
equity
|
Minority
interest
|
Total
equity
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2005 | 572 | 1,803 | 22 | 142 | 876 | 3,415 | 161 | 3,576 | ||||||||
Changes in fair value of derivatives | 16 | 16 | 16 | |||||||||||||
Changes in exchange rates in respect of subsidiaries, associates and joint ventures | (15 | ) | (15 | ) | (1 | ) | (16 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(expense) directly recognized in equity | 16 | (15 | ) | 1 | (1 | ) | | |||||||||
Profit for the period | 249 | 249 | 4 | 253 | ||||||||||||
Total income/(expenses) | 16 | (15 | ) | 249 | 250 | 3 | 253 | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend paid | (2 | ) | (2 | ) | ||||||||||||
Equity-settled transactions | 4 | 4 | 4 | |||||||||||||
Issue of common shares | | 5 | 5 | 5 | ||||||||||||
Changes in minority interest in subsidiaries | (10 | ) | (10 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2006 | 572 | 1,808 | 38 | 127 | 1,129 | 3,674 | 152 | 3,826 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2006 | 574 | 1,841 | (2 | ) | 30 | 1,701 | 4,144 | 119 | 4,263 | |||||||
Changes in fair value of derivatives | (5 | ) | (5 | ) | (5 | ) | ||||||||||
Changes in exchange rates in respect of subsidiaries, associates and joint ventures | (29 | ) | (29 | ) | (1 | ) | (30 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income/(expenses) directly recognized in equity | (5 | ) | (29 | ) | (34 | ) | (1 | ) | (35 | ) | ||||||
Profit for the period | 246 | 246 | 8 | 254 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income/(expenses) | (5 | ) | (29 | ) | 246 | 212 | 7 | 219 | ||||||||
Dividend paid | (8 | ) | (8 | ) | ||||||||||||
Equity-settled transactions | 5 | 5 | 5 | |||||||||||||
Issue of common shares | 1 | 34 | 35 | 35 | ||||||||||||
Changes in minority interests in subsidiaries | (1 | ) | (1 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2007 | 575 | 1,875 | (7 | ) | 1 | 1,952 | 4,396 | 117 | 4,513 | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash position virtually
unchanged Capital expenditures amounted to EUR 83 million, up EUR 17 million on the 2006 first quarter level. Capital expenditures were 101% of depreciation (2006: 75%). Expenditures were up both at Coatings at Chemicals. Proceeds from the sale of interests both in 2007 and 2006 related to installment payments for the divestment of a Coatings plant near Barcelona, Spain (divested in 2006) and to the sale of several Chemicals activities under the divestment program initiated in 2005.
|
Strong financial
position Equity rose EUR 250 million, mainly as a result of first quarter income. During the first quarter of 2007, 647,649 stock options were exercised. These options were fulfilled by 407,739 new common shares being issued and 239,910 common shares already held by the company. The company will start a share buyback program for EUR 1.6 billion on May 3, 2007. Subject to shareholder approval at the Annual General Meeting of Shareholders on April 25, 2007, these shares will be cancelled. The companys strong financial position further improved with net interest-bearing borrowings dropping EUR 0.1 billion to EUR 1.0 billion. As a consequence, gearing improved to 0.21 (December 31, 2006: 0.26). |
Condensed consolidated statement of cash flows | |
Changes in equity | |
Report for the 1st quarter of 2007 |
12 | Report for the 1st quarter of 2007 |
Information on segments and incidentals |
Millions
of euros or %
|
1st
quarter
|
||||||
|
|
|
|
|
|
|
|
2007 | 2006 | 1 | Δ% | ||||
Revenues | |||||||
Coatings | 1,554 | 1,434 | 8 | ||||
Chemicals | 917 | 912 | 1 | ||||
Other/eliminations | 30 | 126 | |||||
|
|
||||||
Total | 2,501 | 2,472 | 1 | ||||
|
|
||||||
EBITDA before incidentals | |||||||
Coatings | 153 | 138 | 11 | ||||
Chemicals | 164 | 163 | 1 | ||||
Other | (10 | ) | (22 | ) | |||
|
|
||||||
Total | 307 | 279 | 10 | ||||
|
|
||||||
EBITDA margin | 12.3 | 11.3 | |||||
EBIT (operating income) before incidentals | |||||||
Coatings | 117 | 104 | 13 | ||||
Chemicals | 115 | 108 | 6 | ||||
Other | (13 | ) | (27 | ) | |||
|
|
||||||
Total | 219 | 185 | 18 | ||||
|
|
||||||
EBIT margin | 8.8 | 7.5 | |||||
EBIT (operating income) | |||||||
Coatings | 114 | 209 | (45 | ) | |||
Chemicals | 111 | 80 | 39 | ||||
Other | (13 | ) | (57 | ) | |||
|
|
||||||
Total | 212 | 232 | (9 | ) | |||
|
|
||||||
EBIT margin | 8.5 | 9.4 | |||||
|
|
|
|
|
|
|
|
Incidentals | |||||||
Results on divestments | (3 | ) | 128 | ||||
Restructuring and impairment charges | (4 | ) | (38 | ) | |||
Charges related to major legal, antitrust, and environmental cases | (43 | ) | |||||
|
|
||||||
Total incidentals | (7 | ) | 47 | ||||
|
|
|
|
|
|
|
1 The figures for 2006 have been restated because Chemicals activities (to be) divested have now been included under Other at company level.
Akzo
Nobel
|
13
|
|
Information
on discontinued operations Organon BioSciences |
Millions
of euros or %
|
Organon
|
Intervet
|
Organon
BioSciences
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
2007 | 2006 | Δ% | 2007 | 2006 | Δ% | 2007 | 2006 | Δ% | ||||||||||
Revenues | 626 | 644 | (3 | ) | 300 | 282 | 6 | 920 | 920 | | ||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||
EBIT before incidentals | 84 | 84 | | 65 | 58 | 12 | 147 | 142 | 4 | |||||||||
EBIT margin | 13.4 | 13.0 | 21.7 | 20.6 | 16.0 | 15.4 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||
EBIT (Operating income) | 87 | 80 | 9 | 64 | 58 | 10 | 149 | 138 | 8 | |||||||||
EBIT margin | 13.9 | 12.6 | 21.3 | 20.6 | 16.2 | 15.0 | ||||||||||||
S&D expenses as % of revenues | 32.4 | 31.9 | 22.9 | 24.1 | 29.6 | 29.7 | ||||||||||||
R&D expenses as % of revenues | 18.2 | 19.2 | 9.3 | 9.6 | 15.4 | 16.5 | ||||||||||||
Capital expenditures | 26 | 16 | 11 | 8 | 37 | 24 | ||||||||||||
Invested capital | 1,576 | 1,579 | 1 | 967 | 949 | 1 | 2,599 | 2,556 | 1 | |||||||||
Number of employees | 13,650 | 13,760 | 1 | 5,420 | 5,370 | 1 | 19,140 | 19,190 | 1 | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The minor differences between
the Organon BioSciences figures and the sum of the Organon and Intervet amounts
relate to other activities and eliminations. The numbers of Organon include
the Nobilon activity.
1 At December
31.
On March 12, 2007, the company announced its intention to divest Organon BioSciences (OBS) to Schering-Plough, following their binding cash offer of EUR 11 billion. As a consequence, in accordance with IFRS 5, the OBS activities qualify as so-called discontinued operation. As a result, going forward no depreciation or amortization is recognized anymore for the OBS activities, which increased pre-tax results by EUR 5 million. Organon Operating income before incidentals was unchanged at EUR 84 million. The effect of lower revenues and increased marketing expenditures in the United States were offset by lower R&D expenses and deprecation and amortization charges. As a percentage of revenues, R&D expenses decreased from 19.2% to 18.2% in the first quarter of 2007. For further details on the development of sales of Organons key products, see the Akzo Nobel website at www.akzonobel.com/ investorrelations/financialfaq. Intervet |
The North American activities turned in healthy autonomous growth, in spite of severe weather conditions in the Midwest. However, revenues in that region were affected by the weaker U.S. dollar and divestments. Sales in the other regions of the world were also affected by weaker currencies. In total, currencies had a 4% negative impact and divestments caused a 2% revenues reduction. Mainly as a result of the revenues growth achieved, operating income before incidentals increased by 12% to EUR 65 million. This translates into a healthy EBIT margin of 21.7%. Arnhem, April 24, 2007 The Board of Management |
Information on segments and incidentals | |
Information on the discontinued operations | |
Organon BioSciences | |
Report for the 1st quarter of 2007 |
14 | Report for the 1st quarter of 2007 |
Discontinued operations statement of income | ||||||
Millions of euros |
1st
quarter
|
|||||
|
|
|
|
|||
2007 | 2006 | Δ% | ||||
Revenues | 920 | 920 | | |||
Expenses | (774 | ) | (780 | ) | ||
|
|
|||||
Profit before tax | 146 | 140 | ||||
Income taxes | (34 | ) | (41 | ) | ||
|
|
|||||
Income from discontinued operations | 112 | 99 | 13 | |||
|
||||||
Assets and liabilities held for sale of Organon BioSciences | ||
Millions of euros |
March
31, 2007
|
|
|
|
|
Property, plant and equipment | 1,093 | |
Intangible assets | 153 | |
Financial noncurrent assets | 361 | |
Inventories | 851 | |
Receivables | 814 | |
|
||
Assets held for sale | 3,272 | |
Noncurrent liabilities | 302 | |
Short-term borrowings | 106 | |
Current payables | 682 | |
|
||
Liabilities held for sale | 1,090 | |
|
|
Note: Cash and cash equivalents reported for Organon BioSciences are not included in assets held for sale as these will be settled with the purchase price at the closing of the deal.
The report for the 2nd quarter of 2007 will be published on July 24, 2007.
Notes
The data in this report are
unaudited.
This interim financial report is in compliance with IAS 34 Interim Financial Reporting. The same accounting policies and methods of computation have been applied as in the 2006 financial statements, a copy of which can be found on the companys website www.akzonobel.com.
Revenues consist of sales of goods and services, and royalty income.
Autonomous growth is defined as the change in revenues attributable to changed volumes and selling prices. It excludes currency, acquisition, and divestment effects.
Incidentals are special benefits, results on divestments, restructuring and impairment charges, and charges related to major legal, antitrust, and environmental cases. Operating income excluding incidentals is one of the key figures management uses to assess the companys performance, as this figure better reflects the underlying trends in the results of the activities.
EBIT margin is operating income (EBIT) as percentage of revenues.
EBITDA is EBIT before depreciation and amortization.
Invested capital is total assets less cash and cash equivalents, less current liabilities.
Moving average ROI is EBIT before incidentals of the last four quarters divided by the average invested capital of those four quarters.
Safe Harbor Statement*
This report contains statements
which address such key issues as Akzo Nobels growth strategy, future financial
results, market positions, product development, pharmaceutical products in the
pipeline, and product approvals. Such statements should be carefully considered,
and it should be understood that many factors could cause forecasted and actual
results to differ from these statements. These factors include, but are not
limited to, price fluctuations, currency fluctuations, progress of drug development,
clinical testing and regulatory approval, developments in raw material and personnel
costs, pensions, physical and environmental risks, legal issues, and legislative,
fiscal, and other regulatory measures. Stated competitive positions are based
on management estimates supported by information provided by specialized external
agencies. For a more comprehensive discussion of the risk factors affecting
our business please see our Annual Report on Form 20-F filed with the United
States Securities and Exchange Commission, a copy of which can be found on the
companys corporate website www.akzonobel.com. The 2006 Annual Report on
Form 20-F will be available at the end of the second quarter of 2007.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
Akzo
Nobel
|
15
|
Contact details | ||
Akzo Nobel NV | ||
Velperweg 76 | ||
P.O. Box 9300 | ||
6800 SB Arnhem, the Netherlands | ||
Tel:
|
+31
26 366 4433
|
|
Fax:
|
+31
26 366 3250
|
|
Internet:
|
www.akzonobel.com
|
|
For more information: | ||
The explanatory sheets used by the CFO during the press | ||
conference can be viewed on Akzo Nobels corporate website | ||
www.akzonobel.com. | ||
Akzo Nobel Corporate Communications | ||
Tel: |
+31
26 366 2241
|
|
Fax: |
+31
26 366 5850
|
|
E-mail: |
info@akzonobel.com
|
|
Akzo Nobel Investor Relations | ||
Tel: |
+31
26 366 4317
|
|
Fax: |
+31
26 366 5797
|
|
E-mail: |
investor.relations@akzonobel.com
|
|
Financial calendar |
Annual Meeting of Shareholders
April 25, 2007
Quotation ex 2006 final
dividend
April 27, 2007
Start of the share buyback
program
May 3, 2007
Payment of 2006 final dividend
May 7, 2007
Report for the 2nd quarter
2007
July 24, 2007
Report for the 3rd quarter
2007
October 23, 2007
Quotation ex 2007 interim
dividend
October 24, 2007
Payment of 2007 interim
dividend
October 31, 2007
Contact details and financial calendar | |
Report for the 1st quarter of 2007 |
16 | Report for the 1st quarter of 2007 |
Key brands Akzo Nobel |